Related Experiment Video
Updated: Feb 26, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility
Bradley C Holland1, Zubin Shetty2, Shaheen Alanee3
1Department of Surgery, Division of Urology, Southern Illinois University School of Medicine, Springfield, IL, USA.
Purpose Of Review:
Targeted therapy for genitourinary cancer is being used at an increasing rate. These medications show great survival benefit but are relatively lacking in long-term adverse effect data. With increasing survivability, measures to improve quality of life must be considered for GU cancer and a large proponent of this is sexual function.
Recent Findings:
mTOR inhibitors have shown an effect on testosterone levels and may have a link to abnormal semen parameters. Tyrosine kinase inhibitors (TKIs) have shown no adverse sexual outcomes in the literature. There are laboratory links to tyrosine kinases having a beneficial effect on erectile and sexual function. Possible sexual side effects must be discussed with patients receiving a diagnosis of cancer. Further research is required to determine the exact mechanisms and outcomes of sexual function with new and emerging targeted therapy.
Insights
Targeted therapies for genitourinary cancers offer survival benefits but may impact sexual function. mTOR inhibitors may affect testosterone and semen, while tyrosine kinase inhibitors (TKIs) show no adverse sexual outcomes.
Area of Science:
- Oncology
- Urology
- Pharmacology
Background:
- Targeted therapy use is increasing for genitourinary (GU) cancers.
- These treatments improve survival but have limited long-term adverse effect data.
- Quality of life, particularly sexual function, is crucial for long-term cancer survivors.
Purpose of the Study:
- To review the impact of targeted therapies on sexual function in genitourinary cancer patients.
- To identify potential adverse sexual effects associated with specific targeted drug classes.
- To highlight the need for discussing sexual health in cancer care.
Main Methods:
- Literature review of targeted therapies for GU cancers.
- Analysis of studies reporting on sexual function outcomes.
- Examination of drug class-specific effects on sexual health.
Main Results:
- mTOR inhibitors may affect testosterone levels and semen parameters.
- Tyrosine kinase inhibitors (TKIs) have not been linked to adverse sexual outcomes in current literature.
- Laboratory studies suggest potential benefits of tyrosine kinases for erectile function.
Conclusions:
- Sexual side effects of targeted therapies for GU cancer require careful patient discussion.
- Further research is needed to elucidate mechanisms and long-term outcomes of sexual function with emerging targeted therapies.
Related Concept Videos
Nursing Assessment of the Genitourinary System I: Health History
Targeted Cancer Therapies
There are several types of targeted therapies against...
Infertility in Males
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Spermatogenesis
Urinary Tract Infection IV: Nursing Management

